TSE:MDNA

Medicenna Therapeutics Competitors

C$4.82

-0.03 (-0.62 %)

(As of 04/20/2021 03:59 PM ET)

Add

Compare

Today's Range

C$4.74

Now: C$4.82▼

C$4.93

50-Day Range

C$4.46

MA: C$4.99▼

C$5.38

52-Week Range

C$3.06

Now: C$4.82▼

C$7.25

Volume67,909 shs

Average Volume113,187 shs

Market CapitalizationC$254.99 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Medicenna Therapeutics (TSE:MDNA) Vs. APS, BU, BLU, TH, NRI, and PLI

Should you be buying MDNA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Medicenna Therapeutics, including Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

Medicenna Therapeutics vs. Aptose Biosciences Stock

Aptose Biosciences (TSE:APS) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aptose Biosciences and Medicenna Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0	0	2	0	3.00
Medicenna Therapeutics	0	0	0	0	N/A

Aptose Biosciences presently has a consensus price target of C$12.00, indicating a potential upside of 97.37%. Given Aptose Biosciences' higher probable upside, research analysts plainly believe Aptose Biosciences is more favorable than Medicenna Therapeutics.

Profitability

This table compares Aptose Biosciences and Medicenna Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	N/A	N/A
Medicenna Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Aptose Biosciences and Medicenna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	N/A	C($0.84)	-7.20
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-15.60

Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Aptose Biosciences beats Medicenna Therapeutics on 3 of the 4 factors compared between the two stocks.

Medicenna Therapeutics vs. Burcon NutraScience Stock

Medicenna Therapeutics (TSE:MDNA) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and Burcon NutraScience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0	0	0	0	N/A
Burcon NutraScience	0	0	1	0	3.00

Burcon NutraScience has a consensus price target of C$5.00, indicating a potential downside of 1.19%. Given Burcon NutraScience's higher probable upside, analysts clearly believe Burcon NutraScience is more favorable than Medicenna Therapeutics.

Profitability

This table compares Medicenna Therapeutics and Burcon NutraScience's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	N/A	N/A	N/A
Burcon NutraScience	N/A	N/A	N/A

Earnings & Valuation

This table compares Medicenna Therapeutics and Burcon NutraScience's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-15.60
Burcon NutraScience	C$12,045.00	44,992.20	C$107,101.00	C$0.00	5,060.00

Burcon NutraScience has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats Medicenna Therapeutics on 5 of the 5 factors compared between the two stocks.

Medicenna Therapeutics vs. BELLUS Health Stock

Medicenna Therapeutics (TSE:MDNA) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and BELLUS Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0	0	0	0	N/A
BELLUS Health	0	1	2	0	2.67

Profitability

This table compares Medicenna Therapeutics and BELLUS Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	N/A	N/A	N/A
BELLUS Health	N/A	N/A	N/A

Earnings & Valuation

This table compares Medicenna Therapeutics and BELLUS Health's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-15.60
BELLUS Health	C$15,000.00	29,298.04	C$-52,720,801.00	C($0.67)	-8.34

Medicenna Therapeutics has higher earnings, but lower revenue than BELLUS Health. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Summary

BELLUS Health beats Medicenna Therapeutics on 3 of the 4 factors compared between the two stocks.

Medicenna Therapeutics vs. Theratechnologies Stock

Medicenna Therapeutics (TSE:MDNA) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares Medicenna Therapeutics and Theratechnologies' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-15.60
Theratechnologies	C$65.76 million	6.47	C$-35,948,380.00	C($0.38)	-11.84

Medicenna Therapeutics has higher earnings, but lower revenue than Theratechnologies. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicenna Therapeutics and Theratechnologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	N/A	N/A	N/A
Theratechnologies	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and price targets for Medicenna Therapeutics and Theratechnologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicenna Therapeutics	0	0	0	0	N/A
Theratechnologies	0	2	0	0	2.00

Theratechnologies has a consensus price target of C$3.75, indicating a potential downside of 16.67%. Given Theratechnologies' higher probable upside, analysts clearly believe Theratechnologies is more favorable than Medicenna Therapeutics.

Summary

Theratechnologies beats Medicenna Therapeutics on 3 of the 4 factors compared between the two stocks.

Medicenna Therapeutics vs. Nuvo Pharmaceuticals Inc. (NRI.TO) Stock

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Valuation and Earnings

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Medicenna Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)	C$76.09 million	5.29	C$-6,980,844.00	C($0.61)	-57.68
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-15.60

Medicenna Therapeutics has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and Medicenna Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)	N/A	N/A	N/A
Medicenna Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and Medicenna Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)	0	0	1	0	3.00
Medicenna Therapeutics	0	0	0	0	N/A

Medicenna Therapeutics vs. ProMetic Life Sciences Stock

ProMetic Life Sciences (TSE:PLI) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Valuation and Earnings

This table compares ProMetic Life Sciences and Medicenna Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	C$39.91 million	0.00	C$-1,470,117,780.00	C($63.06)	N/A
Medicenna Therapeutics	N/A	N/A	N/A	C($0.31)	-15.60

Medicenna Therapeutics has lower revenue, but higher earnings than ProMetic Life Sciences. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProMetic Life Sciences and Medicenna Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	N/A	N/A	N/A
Medicenna Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ProMetic Life Sciences and Medicenna Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMetic Life Sciences	0	0	0	0	N/A
Medicenna Therapeutics	0	0	0	0	N/A

Summary

ProMetic Life Sciences beats Medicenna Therapeutics on 2 of the 3 factors compared between the two stocks.